| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$14.1M | ROE | −372.97% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $8.4M | Trading Days | 2128 |
| 52W High | 14.25 |
| 52W Low | 1.67 |
| % Off High | −78.60% |
| YTD | 5.90% | 1Y | −47.41% |
| 3Y | −98.60% | 5Y | −99.91% |
| 10Y | −99.96% | Since incept. (ann.) | −53.58% |
| Ann. Volatility (1Y) | 183.67% | Ann. Volatility (3Y) | 178.24% |
| Sharpe (1Y) | 0.42 | Sharpe (3Y) | −0.06 |
| Max Drawdown (1Y) | −84.55% | Max Drawdown (3Y) | −99.56% |
| Beta (3Y, vs SPY) | 2.17 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SYBX | SYNLOGIC, INC. | $7.8M | — |
| TRAW | Traws Pharma, Inc. | $7.8M | 0.6 |
| BOLT | Bolt Biotherapeutics, Inc. | $7.7M | — |
| APRE | Aprea Therapeutics, Inc. | $7.6M | — |
| CNSP | CNS Pharmaceuticals, Inc. | $7.4M | — |
| MTVA | MetaVia Inc. | $7.4M | — |
| VTGN | Vistagen Therapeutics, Inc. | $9.6M | — |
| BIVI | BIOVIE INC. | $10.0M | — |
| AEON | AEON Biopharma, Inc. | $6.7M | — |
| LSTA | LISATA THERAPEUTICS, INC. | $10.6M | — |
| LGVN | Longeveron Inc. | $10.6M | — |
| KAPA | Kairos Pharma, LTD. | $6.6M | — |
